Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

A New Mouse Line Reporting the Translation of Brain-Derived Neurotrophic Factor Using Green Fluorescent Protein.

Wosnitzka E, Nan X, Nan J, Chacón-Fernández P, Kussmaul L, Schuler M, Hengerer B, Barde YA.

eNeuro. 2020 Jan 9;7(1). pii: ENEURO.0462-19.2019. doi: 10.1523/ENEURO.0462-19.2019. Print 2020 Jan/Feb.

2.

RFID-supported video tracking for automated analysis of social behaviour in groups of mice.

Peleh T, Bai X, Kas MJH, Hengerer B.

J Neurosci Methods. 2019 Sep 1;325:108323. doi: 10.1016/j.jneumeth.2019.108323. Epub 2019 Jun 27. Review.

3.

Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia.

Al Shweiki MR, Steinacker P, Oeckl P, Hengerer B, Danek A, Fassbender K, Diehl-Schmid J, Jahn H, Anderl-Straub S, Ludolph AC, Schönfeldt-Lecuona C, Otto M.

J Psychiatr Res. 2019 Jun;113:137-140. doi: 10.1016/j.jpsychires.2019.03.019. Epub 2019 Mar 24.

PMID:
30953863
4.

The reverse translation of a quantitative neuropsychiatric framework into preclinical studies: Focus on social interaction and behavior.

Peleh T, Ike KGO, Wams EJ, Lebois EP, Hengerer B.

Neurosci Biobehav Rev. 2019 Feb;97:96-111. doi: 10.1016/j.neubiorev.2018.07.018. Epub 2019 Jan 16. Review.

5.

Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model.

Pagliaroli L, Widomska J, Nespoli E, Hildebrandt T, Barta C, Glennon J, Hengerer B, Poelmans G.

Mol Neurobiol. 2019 Jul;56(7):5111-5121. doi: 10.1007/s12035-018-1433-x. Epub 2018 Nov 27.

6.

Chronic Social Stress Leads to Reduced Gustatory Reward Salience and Effort Valuation in Mice.

Kúkel'ová D, Bergamini G, Sigrist H, Seifritz E, Hengerer B, Pryce CR.

Front Behav Neurosci. 2018 Jul 10;12:134. doi: 10.3389/fnbeh.2018.00134. eCollection 2018.

7.

Altered dopaminergic regulation of the dorsal striatum is able to induce tic-like movements in juvenile rats.

Nespoli E, Rizzo F, Boeckers T, Schulze U, Hengerer B.

PLoS One. 2018 Apr 26;13(4):e0196515. doi: 10.1371/journal.pone.0196515. eCollection 2018.

8.

Oligodendrocyte gene expression is reduced by and influences effects of chronic social stress in mice.

Cathomas F, Azzinnari D, Bergamini G, Sigrist H, Buerge M, Hoop V, Wicki B, Goetze L, Soares S, Kukelova D, Seifritz E, Goebbels S, Nave KA, Ghandour MS, Seoighe C, Hildebrandt T, Leparc G, Klein H, Stupka E, Hengerer B, Pryce CR.

Genes Brain Behav. 2019 Jan;18(1):e12475. doi: 10.1111/gbb.12475. Epub 2018 Apr 17.

PMID:
29566304
9.

Aripiprazole Selectively Reduces Motor Tics in a Young Animal Model for Tourette's Syndrome and Comorbid Attention Deficit and Hyperactivity Disorder.

Rizzo F, Nespoli E, Abaei A, Bar-Gad I, Deelchand DK, Fegert J, Rasche V, Hengerer B, Boeckers TM.

Front Neurol. 2018 Feb 13;9:59. doi: 10.3389/fneur.2018.00059. eCollection 2018.

10.

Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice.

Just S, Chenard BL, Ceci A, Strassmaier T, Chong JA, Blair NT, Gallaschun RJ, Del Camino D, Cantin S, D'Amours M, Eickmeier C, Fanger CM, Hecker C, Hessler DP, Hengerer B, Kroker KS, Malekiani S, Mihalek R, McLaughlin J, Rast G, Witek J, Sauer A, Pryce CR, Moran MM.

PLoS One. 2018 Jan 31;13(1):e0191225. doi: 10.1371/journal.pone.0191225. eCollection 2018.

11.

Trial watch: Tracing investment in drug development for Alzheimer disease.

Kodamullil AT, Zekri F, Sood M, Hengerer B, Canard L, McHale D, Hofmann-Apitius M.

Nat Rev Drug Discov. 2017 Dec;16(12):819. doi: 10.1038/nrd.2017.169. Epub 2017 Oct 23. No abstract available.

PMID:
29056749
12.

Proteasome impairment by α-synuclein.

Zondler L, Kostka M, Garidel P, Heinzelmann U, Hengerer B, Mayer B, Weishaupt JH, Gillardon F, Danzer KM.

PLoS One. 2017 Sep 25;12(9):e0184040. doi: 10.1371/journal.pone.0184040. eCollection 2017.

13.

Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal 1H-NMR spectroscopy study at 11.7T.

Rizzo F, Abaei A, Nespoli E, Fegert JM, Hengerer B, Rasche V, Boeckers TM.

Transl Psychiatry. 2017 Aug 1;7(8):e1189. doi: 10.1038/tp.2017.167.

14.

Novel Blood-Based Biomarkers of Cognition, Stress, and Physical or Cognitive Training in Older Adults at Risk of Dementia: Preliminary Evidence for a Role of BDNF, Irisin, and the Kynurenine Pathway.

Küster OC, Laptinskaya D, Fissler P, Schnack C, Zügel M, Nold V, Thurm F, Pleiner S, Karabatsiakis A, von Einem B, Weydt P, Liesener A, Borta A, Woll A, Hengerer B, Kolassa IT, von Arnim CAF.

J Alzheimers Dis. 2017;59(3):1097-1111. doi: 10.3233/JAD-170447.

PMID:
28731451
15.

Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies.

Al Shweiki MR, Oeckl P, Steinacker P, Hengerer B, Schönfeldt-Lecuona C, Otto M.

Expert Rev Proteomics. 2017 Jun;14(6):499-514. doi: 10.1080/14789450.2017.1336435. Review.

PMID:
28562112
16.

TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome.

Forde NJ, Kanaan AS, Widomska J, Padmanabhuni SS, Nespoli E, Alexander J, Rodriguez Arranz JI, Fan S, Houssari R, Nawaz MS, Rizzo F, Pagliaroli L, Zilhäo NR, Aranyi T, Barta C, Boeckers TM, Boomsma DI, Buisman WR, Buitelaar JK, Cath D, Dietrich A, Driessen N, Drineas P, Dunlap M, Gerasch S, Glennon J, Hengerer B, van den Heuvel OA, Jespersgaard C, Möller HE, Müller-Vahl KR, Openneer TJ, Poelmans G, Pouwels PJ, Scharf JM, Stefansson H, Tümer Z, Veltman DJ, van der Werf YD, Hoekstra PJ, Ludolph A, Paschou P.

Front Neurosci. 2016 Aug 23;10:384. doi: 10.3389/fnins.2016.00384. eCollection 2016.

17.

Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model.

Scheffold A, Holtman IR, Dieni S, Brouwer N, Katz SF, Jebaraj BM, Kahle PJ, Hengerer B, Lechel A, Stilgenbauer S, Boddeke EW, Eggen BJ, Rudolph KL, Biber K.

Acta Neuropathol Commun. 2016 Aug 22;4(1):87. doi: 10.1186/s40478-016-0364-x.

18.

LC-MS/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid and brain.

Fuertig R, Ceci A, Camus SM, Bezard E, Luippold AH, Hengerer B.

Bioanalysis. 2016 Sep;8(18):1903-17. doi: 10.4155/bio-2016-0111. Epub 2016 Aug 15.

19.

Addressing the Complexity of Tourette's Syndrome through the Use of Animal Models.

Nespoli E, Rizzo F, Boeckers TM, Hengerer B, Ludolph AG.

Front Neurosci. 2016 Apr 8;10:133. doi: 10.3389/fnins.2016.00133. eCollection 2016. Review.

20.

Peripheral monocytes are functionally altered and invade the CNS in ALS patients.

Zondler L, Müller K, Khalaji S, Bliederhäuser C, Ruf WP, Grozdanov V, Thiemann M, Fundel-Clemes K, Freischmidt A, Holzmann K, Strobel B, Weydt P, Witting A, Thal DR, Helferich AM, Hengerer B, Gottschalk KE, Hill O, Kluge M, Ludolph AC, Danzer KM, Weishaupt JH.

Acta Neuropathol. 2016 Sep;132(3):391-411. doi: 10.1007/s00401-016-1548-y. Epub 2016 Feb 24.

PMID:
26910103
21.

Mouse chronic social stress increases blood and brain kynurenine pathway activity and fear behaviour: Both effects are reversed by inhibition of indoleamine 2,3-dioxygenase.

Fuertig R, Azzinnari D, Bergamini G, Cathomas F, Sigrist H, Seifritz E, Vavassori S, Luippold A, Hengerer B, Ceci A, Pryce CR.

Brain Behav Immun. 2016 May;54:59-72. doi: 10.1016/j.bbi.2015.12.020. Epub 2015 Dec 24.

PMID:
26724575
22.

Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes.

Bliederhaeuser C, Grozdanov V, Speidel A, Zondler L, Ruf WP, Bayer H, Kiechle M, Feiler MS, Freischmidt A, Brenner D, Witting A, Hengerer B, Fändrich M, Ludolph AC, Weishaupt JH, Gillardon F, Danzer KM.

Acta Neuropathol. 2016 Mar;131(3):379-91. doi: 10.1007/s00401-015-1504-2. Epub 2015 Nov 17.

PMID:
26576561
23.

CD40-TNF activation in mice induces extended sickness behavior syndrome co-incident with but not dependent on activation of the kynurenine pathway.

Cathomas F, Fuertig R, Sigrist H, Newman GN, Hoop V, Bizzozzero M, Mueller A, Luippold A, Ceci A, Hengerer B, Seifritz E, Fontana A, Pryce CR.

Brain Behav Immun. 2015 Nov;50:125-140. doi: 10.1016/j.bbi.2015.06.184. Epub 2015 Jul 11.

PMID:
26173174
24.

Inflammatory dysregulation of blood monocytes in Parkinson's disease patients.

Grozdanov V, Bliederhaeuser C, Ruf WP, Roth V, Fundel-Clemens K, Zondler L, Brenner D, Martin-Villalba A, Hengerer B, Kassubek J, Ludolph AC, Weishaupt JH, Danzer KM.

Acta Neuropathol. 2014 Nov;128(5):651-63. doi: 10.1007/s00401-014-1345-4. Epub 2014 Oct 5.

25.

Mouse social stress induces increased fear conditioning, helplessness and fatigue to physical challenge together with markers of altered immune and dopamine function.

Azzinnari D, Sigrist H, Staehli S, Palme R, Hildebrandt T, Leparc G, Hengerer B, Seifritz E, Pryce CR.

Neuropharmacology. 2014 Oct;85:328-41. doi: 10.1016/j.neuropharm.2014.05.039. Epub 2014 Jun 5.

26.

Identification and affinity-quantification of ß-amyloid and α-synuclein polypeptides using on-line SAW-biosensor-mass spectrometry.

Slamnoiu S, Vlad C, Stumbaum M, Moise A, Lindner K, Engel N, Vilanova M, Diaz M, Karreman C, Leist M, Ciossek T, Hengerer B, Vilaseca M, Przybylski M.

J Am Soc Mass Spectrom. 2014 Aug;25(8):1472-81. doi: 10.1007/s13361-014-0904-1. Epub 2014 May 21.

PMID:
24845351
27.

G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease.

Oeckl P, Hengerer B, Ferger B.

Exp Neurol. 2014 Jul;257:1-9. doi: 10.1016/j.expneurol.2014.04.010. Epub 2014 Apr 18.

PMID:
24747358
28.

Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity.

Höllerhage M, Goebel JN, de Andrade A, Hildebrandt T, Dolga A, Culmsee C, Oertel WH, Hengerer B, Höglinger GU.

Neurobiol Aging. 2014 Jul;35(7):1700-11. doi: 10.1016/j.neurobiolaging.2014.01.027. Epub 2014 Jan 28.

PMID:
24559643
29.

Nondopaminergic neurotransmission in the pathophysiology of Tourette syndrome.

Udvardi PT, Nespoli E, Rizzo F, Hengerer B, Ludolph AG.

Int Rev Neurobiol. 2013;112:95-130. doi: 10.1016/B978-0-12-411546-0.00004-4. Review.

PMID:
24295619
30.

Globular and protofibrillar aβ aggregates impair neurotransmission by different mechanisms.

Moreth J, Kroker KS, Schwanzar D, Schnack C, von Arnim CA, Hengerer B, Rosenbrock H, Kussmaul L.

Biochemistry. 2013 Feb 26;52(8):1466-76. doi: 10.1021/bi3016444. Epub 2013 Feb 14.

PMID:
23374097
31.

ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?

Gillardon F, Kremmer E, Froehlich T, Ueffing M, Hengerer B, Gloeckner CJ.

J Neurosci Methods. 2013 Mar 30;214(1):62-8. doi: 10.1016/j.jneumeth.2012.12.015. Epub 2013 Jan 12.

PMID:
23318290
32.

Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia.

Jesse S, Lehnert S, Jahn O, Parnetti L, Soininen H, Herukka SK, Steinacker P, Tawfik S, Tumani H, von Arnim CA, Neumann M, Kretzschmar HA, Kulaksiz H, Lenter M, Wiltfang J, Ferger B, Hengerer B, Otto M.

PLoS One. 2012;7(11):e48783. doi: 10.1371/journal.pone.0048783. Epub 2012 Nov 8.

33.

Characterization of oligomerization-aggregation products of neurodegenerative target proteins by ion mobility mass spectrometry.

Vlad C, Iurascu MI, Slamnoiu S, Hengerer B, Przybylski M.

Methods Mol Biol. 2012;896:399-412. doi: 10.1007/978-1-4614-3704-8_27.

PMID:
22821540
34.

iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia.

Lehnert S, Jesse S, Rist W, Steinacker P, Soininen H, Herukka SK, Tumani H, Lenter M, Oeckl P, Ferger B, Hengerer B, Otto M.

Exp Neurol. 2012 Apr;234(2):499-505. doi: 10.1016/j.expneurol.2012.01.024. Epub 2012 Feb 1.

PMID:
22327139
35.

Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson's disease protein alpha-synuclein as revealed by ion mobility mass spectrometry.

Vlad C, Lindner K, Karreman C, Schildknecht S, Leist M, Tomczyk N, Rontree J, Langridge J, Danzer K, Ciossek T, Petre A, Gross ML, Hengerer B, Przybylski M.

Chembiochem. 2011 Dec 16;12(18):2740-4. doi: 10.1002/cbic.201100569. Epub 2011 Nov 7.

36.

AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α-synuclein oligomers.

Hüls S, Högen T, Vassallo N, Danzer KM, Hengerer B, Giese A, Herms J.

J Neurochem. 2011 Jun;117(5):868-78. doi: 10.1111/j.1471-4159.2011.07254.x. Epub 2011 Apr 26.

37.

An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction.

East SP, Bamford S, Dietz MG, Eickmeier C, Flegg A, Ferger B, Gemkow MJ, Heilker R, Hengerer B, Kotey A, Loke P, Schänzle G, Schubert HD, Scott J, Whittaker M, Williams M, Zawadzki P, Gerlach K.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4901-5. doi: 10.1016/j.bmcl.2010.06.078. Epub 2010 Jun 25.

PMID:
20638279
38.

Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism.

Jiang M, Porat-Shliom Y, Pei Z, Cheng Y, Xiang L, Sommers K, Li Q, Gillardon F, Hengerer B, Berlinicke C, Smith WW, Zack DJ, Poirier MA, Ross CA, Duan W.

J Neurochem. 2010 Jul;114(2):419-29. doi: 10.1111/j.1471-4159.2010.06752.x. Epub 2010 Apr 19.

39.

Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology.

Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B.

J Neurochem. 2009 Oct;111(1):192-203. doi: 10.1111/j.1471-4159.2009.06324.x. Epub 2009 Aug 4.

40.

Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M.

CNS Neurosci Ther. 2009 Summer;15(2):157-82. doi: 10.1111/j.1755-5949.2008.00064.x. Epub 2009 Mar 9. Review.

41.

Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.

Schuster S, Doudnikoff E, Rylander D, Berthet A, Aubert I, Ittrich C, Bloch B, Cenci MA, Surmeier DJ, Hengerer B, Bezard E.

Biol Psychiatry. 2009 Mar 15;65(6):518-26. doi: 10.1016/j.biopsych.2008.09.008. Epub 2008 Oct 23.

PMID:
18947822
42.

Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins.

Schnack C, Danzer KM, Hengerer B, Gillardon F.

Neuroscience. 2008 Jul 17;154(4):1450-7. doi: 10.1016/j.neuroscience.2008.02.049. Epub 2008 Feb 29.

PMID:
18541383
43.

Identification of novel substrates for Cdk5 and new targets for Cdk5 inhibitors using high-density protein microarrays.

Schnack C, Hengerer B, Gillardon F.

Proteomics. 2008 May;8(10):1980-6. doi: 10.1002/pmic.200701063.

PMID:
18491313
44.

MicroRNA and proteome expression profiling in early-symptomatic α-synuclein(A30P)-transgenic mice.

Gillardon F, Mack M, Rist W, Schnack C, Lenter M, Hildebrandt T, Hengerer B.

Proteomics Clin Appl. 2008 May;2(5):697-705. doi: 10.1002/prca.200780025. Epub 2008 Apr 9.

PMID:
21136867
45.

The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.

Schuster S, Nadjar A, Guo JT, Li Q, Ittrich C, Hengerer B, Bezard E.

J Neurosci. 2008 Apr 23;28(17):4311-6. doi: 10.1523/JNEUROSCI.4720-07.2008.

46.

Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers.

Danzer KM, Schnack C, Sutcliffe A, Hengerer B, Gillardon F.

J Neurochem. 2007 Dec;103(6):2401-7. Epub 2007 Sep 18.

47.

Different species of alpha-synuclein oligomers induce calcium influx and seeding.

Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M.

J Neurosci. 2007 Aug 22;27(34):9220-32.

48.

Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop.

Ludolph AC, Bendotti C, Blaugrund E, Hengerer B, Löffler JP, Martin J, Meininger V, Meyer T, Moussaoui S, Robberecht W, Scott S, Silani V, Van Den Berg LH; ENMC Group for the Establishment of Guidelines for the Conduct of Preclinical and Proof of Concept Studies in ALS/MND Models.

Amyotroph Lateral Scler. 2007 Aug;8(4):217-23.

PMID:
17653919
49.

Predominant neuritic pathology induced by viral overexpression of alpha-synuclein in cell culture.

Zach S, Bueler H, Hengerer B, Gillardon F.

Cell Mol Neurobiol. 2007 Jun;27(4):505-15. Epub 2007 Mar 23.

PMID:
17380380
50.

Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition.

Gillardon F, Rist W, Kussmaul L, Vogel J, Berg M, Danzer K, Kraut N, Hengerer B.

Proteomics. 2007 Feb;7(4):605-616. doi: 10.1002/pmic.200600728.

PMID:
17309106

Supplemental Content

Loading ...
Support Center